A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Jordi Rodon
Charlotte D. Jacobs
Quincy Chu
Eric K. Rowinsky
Arturo Lopez-Anaya
Chris H. Takimoto
Heather A. Wakelee
机构：
[1] Cancer Therapy and Research Center at The University of Texas Health Science Center,Institute for Drug Development
[2] Stanford University and Stanford Cancer Institute,Division of Oncology, Department of Medicine
[3] Eisai,undefined
[4] Inc.,undefined
[5] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,undefined
[6] Cross Cancer Institute,undefined
[7] University of Alberta,undefined
[8] Oncodrugs Consulting,undefined
[9] Forest Laboratories,undefined
[10] Inc.,undefined
[11] Ortho Biotech Oncology R&D/Johnson & Johnson,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bexarotene; Carboplatin; Paclitaxel; Pharmacokinetics; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：825 / 834
页数：9
相关论文
共 50 条
  • [41] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [42] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [43] A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Mikhaeel-Kamel, N
    Pan, ZX
    Murphy, J
    Prindiville, S
    Bunn, PA
    CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3474 - 3479
  • [44] Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC)
    Camidge, D. R.
    Conkling, P.
    Stephenson, J. J.
    Glassman, P. M.
    Zhao, Y.
    Kaiser, R.
    Stopfer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Review of paclitaxel/carboplatin in advanced non-small cell lung cancer
    Bonomi, P
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 55 - 59
  • [46] Pharmacokinetic interaction study evaluating the effect of BMS-275291 on the pharmacokinetics of paclitaxel and carboplatin in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Malik, SM
    Hwang, JJ
    Belani, CP
    Galbraith, S
    Bai, S
    Rizvi, NA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 693S - 693S
  • [47] Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC).
    McKeage, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 389S - 389S
  • [48] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [49] A phase I, pharmacokinetic (PK), and biological study of FGF inhibition modulating paclitaxel/carboplatin (P/C) chemotherapy in non-small cell lung cancer (NSCLC) patients (pts).
    Villalona-Calero, MA
    Otterson, GA
    Kanter, S
    Young, D
    Fischer, B
    Straiko, M
    Chen, D
    Brooks, R
    Song, S
    Zhang, Y
    Yeh, T
    Chan, K
    Grever, M
    Wientjes, G
    Au, JL
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3738S - 3738S
  • [50] A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Pillot, GA
    Hennenfent, K
    Read, W
    Marsh, S
    McLeod, HL
    Gao, F
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
12345